Monte Rosa Therapeutics
GLUE
$16.52
-27.16%
GLUE price trend
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Monte Rosa Therapeutics's 12-month outlook, with a consensus price target around $34.83 and implied upside of +110.9% versus the current price.
Average Target
$34.83
0 analysts
Implied Upside
+110.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$29 - $40
Analyst target range
GLUE Technical Analysis
Beta
1.56
1.56x market volatility
Max Drawdown
-41.8%
Largest decline past year
52-Week Range
$4-$26
Price range past year
Annual Return
+233.7%
Cumulative gain past year
| Period | GLUE Return | S&P 500 |
|---|---|---|
| 1m | -31.2% | +0.2% |
| 3m | -12.1% | +3.7% |
| 6m | -19.5% | +8.0% |
| 1y | +233.7% | +18.2% |
| ytd | +7.9% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
Valuation Analysis: Is GLUE Overvalued?
PE
-34.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-38.6x
Enterprise Value Multiple